Skip to main content
Premium Trial:

Request an Annual Quote

Axela, Cronus Ink Distribution Deal for UK, Ireland

NEW YORK (GenomeWeb News) – Cronus Technologies and Axela today announced a distribution deal to market Axela's instruments in the UK and Ireland.

Cronus will manage the sales and support of Axela's flow-through systems in both countries under the terms of the deal. The systems include the fully automated Ziplex Research System for gene and protein microarray analysis, and the dotLab mX System for real-time, multiplex immunoassays. Cronus will also market Axela's panelPlus Technology for creating custom multiplex panels for flow-through biomarker analysis.

"The Ziplex and dotLab mX product range adds another string to our biomarker discovery and validation portfolio and allows us to truly collaborate with our customers in a meaningful and strategic way," Kevin Fairman, CEO of Cronus, said in a statement. "This positive addition combined with a great working relationship with the Axela team will allow our customers to push the boundaries and time constraints in biomarker research."

The companies did not reveal the terms of the deal, which follows an agreement Toronto-based Axela inked with Digilab in August to distribute Axela's products in the US.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.